Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
erbitux save search
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Published: 2024-01-16 (Crawled : 12:30) - globenewswire.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 0.15%
H: 0.59%
C: -1.45%
erbitux first cell trial
Innovent Enters into Clinical Trial Collaboration with Merck KGaA, Darmstadt, Germany Investigating Combination Therapy of IBI351 (KRASG12C Inhibitor) and Cetuximab (ERBITUX®)for KRASG12C-mutated NSCLC in China
Published: 2023-06-02 (Crawled : 00:00) - prnewswire.com
SNYNF | $92.966 630
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 0.79%
H: 1.08%
C: 0.54%
SNY | $45.99 0.13% 70K
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
INCY | $53.85 0.79% 100K
|
Health Technology
|
| O: -0.02%
H: 1.79%
C: 1.69%
ibi351 erbitux merck germany collaboration trial china therapy
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
Published: 2022-06-22 (Crawled : 12:00) - investor.aveooncology.com
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 1.31%
H: 0.0%
C: 0.0%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 8.59%
H: 9.93%
C: 5.88%
erbitux america collaboration trial agreement
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
erbitux trial germany collaboration
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE A | $25.955 0.17% 4.8M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
Flatiron Health Real-World Data Support FDA Approval of New Dosing Regimen for ERBITUX® (cetuximab)
Published: 2021-07-20 (Crawled : 16:00) - biospace.com/
LLY | $749.58 -0.16% 450K
|
Health Technology
|
| O: 0.37%
H: 1.17%
C: 0.01%
fda fda approval approval
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
TPET | $0.4801 107.75% 16M
|
n/a
JAGX | $0.23 93.6% 310M
|
Health Technology
WISA 4 | $3.17 81.14% 36M
|
Electronic Technology
PALI | $6.57 57.93% 19M
|
Manufacturing
SPCB | $0.4278 55.0% 17M
|
Electronic Technology
BTTR | $7.61 49.22% 1.8M
|
Manufacturing
PRSO | $1.79 40.95% 38M
|
Manufacturing
DYNT | $0.5203 40.47% 17M
|
Health Technology
MCBC | $13.755 38.52% 620K
|
Finance
SNGX | $0.5155 33.52% 3.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.